BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 16875761)

  • 1. Treatment with infliximab: Implications in oral surgery? A case report.
    Ciantar M; Adlam DM
    Br J Oral Maxillofac Surg; 2007 Sep; 45(6):507-10. PubMed ID: 16875761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sézary syndrome in a patient receiving infliximab for ankylosing spondylitis.
    Dauendorffer JN; Rivet J; Allard A; Bachelez H
    Br J Dermatol; 2007 Apr; 156(4):742-3. PubMed ID: 17263820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A series of complications after third molar osteotomy in a pancytopenia patient and spontaneous healing after bone marrow transplantation.
    Klatt JC; Gröbe A; Schmelzle R; Atac A; Heiland M; Blessmann M; Pohlenz P
    J Oral Maxillofac Surg; 2011 Oct; 69(10):2508-12. PubMed ID: 21571420
    [No Abstract]   [Full Text] [Related]  

  • 4. Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis.
    Chan CY; Browning JC; Larsen F; Hsu S
    Dermatol Online J; 2008 Sep; 14(9):12. PubMed ID: 19061594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteomyelitis of odontogenic origin: report of case and review.
    Beurle JG; Goode M; Higa L
    J Can Dent Assoc (Tor); 1970 Sep; 36(9):338-41. PubMed ID: 5272037
    [No Abstract]   [Full Text] [Related]  

  • 6. Third molar complications requiring hospitalization.
    Kunkel M; Morbach T; Kleis W; Wagner W
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Sep; 102(3):300-6. PubMed ID: 16920537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cryptococcal meningitis in a patient treated with infliximab.
    Muñoz P; Giannella M; Valerio M; Soria T; Díaz F; Longo JL; Bouza E
    Diagn Microbiol Infect Dis; 2007 Apr; 57(4):443-6. PubMed ID: 17240111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extraction of impacted mandibular third molars: postoperative complications and their risk factors.
    Blondeau F; Daniel NG
    J Can Dent Assoc; 2007 May; 73(4):325. PubMed ID: 17484797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do pathologies associated with impacted lower third molars justify prophylactic removal? A critical review of the literature.
    Adeyemo WL
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Oct; 102(4):448-52. PubMed ID: 16997110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disseminated Mycobacterium marinum infection in a patient with rheumatoid arthritis receiving infliximab therapy.
    Danko JR; Gilliland WR; Miller RS; Decker CF
    Scand J Infect Dis; 2009; 41(4):252-5. PubMed ID: 19266397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicity of infliximab in the course of treatment of Crohn's disease.
    Bratcher JM; Korelitz BI
    Expert Opin Drug Saf; 2006 Jan; 5(1):9-16. PubMed ID: 16370952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Third molar surgery: current concepts and controversies. Part 1.
    Sands T; Pynn BR; Nenniger S
    Oral Health; 1993 May; 83(5):11-4, 17. PubMed ID: 8233412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.
    Aringer M; Houssiau F; Gordon C; Graninger WB; Voll RE; Rath E; Steiner G; Smolen JS
    Rheumatology (Oxford); 2009 Nov; 48(11):1451-4. PubMed ID: 19748965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diffuse large B-cell lymphoma in a patient with rheumatoid arthritis treated with infliximab and methotrexate.
    Nakashima C; Tanioka M; Takahashi K; Miyachi Y
    Clin Exp Dermatol; 2008 Jul; 33(4):437-9. PubMed ID: 18485021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Development of tuberculosis after treatment with the TNF-alpha inhibitor infliximab].
    Dahl M; Ravn P
    Ugeskr Laeger; 2005 Jan; 167(5):527-8. PubMed ID: 15745179
    [No Abstract]   [Full Text] [Related]  

  • 16. Accidental displacement of a mandibular third molar: a case report.
    Ozyuvaci H; Firat D; Tanyel C
    Quintessence Int; 2003 Apr; 34(4):278-80. PubMed ID: 12731614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response.
    Braun J; Baraliakos X; Listing J; Fritz C; Alten R; Burmester G; Krause A; Schewe S; Schneider M; Sörensen H; Zeidler H; Sieper J
    Ann Rheum Dis; 2008 Mar; 67(3):340-5. PubMed ID: 17967831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New-onset psoriatic palmoplantaris pustulosis following infliximab therapy: a class effect?
    Roux CH; Brocq O; Leccia N; Giacchero D; Breuil V; Albert C; Lacour J; Perrin C; Euller-Ziegler L
    J Rheumatol; 2007 Feb; 34(2):434-7. PubMed ID: 17295430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complications of third molar surgery.
    Bouloux GF; Steed MB; Perciaccante VJ
    Oral Maxillofac Surg Clin North Am; 2007 Feb; 19(1):117-28, vii. PubMed ID: 18088870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atypical cutaneous tuberculosis in a patient with rheumatoid arthritis treated with infliximab.
    Asano Y; Kano Y; Shiohara T
    Acta Derm Venereol; 2008; 88(2):183-4. PubMed ID: 18311458
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.